Results 301 to 308 of about 107,800 (308)

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

Lancet Oncology, The, 2017
Michele Maio, Arnaud Scherpereel, Joachim Aerts   +2 more
exaly  

Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study

Lancet Oncology, The, 2011
Tom Treasure, Suresh Senan, John G Edwards   +2 more
exaly  

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors

Advances in Anatomic Pathology, 2017
Shona Hendry, Koen Van de Vijver, Melinda E Sanders   +2 more
exaly  

Mesothelioma of the pleura [PDF]

Irish Journal of Medical Science, 1970
openaire   +2 more sources

Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada

Journal of Clinical Oncology, 2005
Jan van Meerbeeck, Rabab Gaafar, Andrew Bottomley   +2 more
exaly  

Malignant Pleural Mesothelioma

Journal of Clinical Oncology, 2009
Anne S Tsao
exaly  

Talc and mesothelioma

Medical Journal of Australia, 1984
openaire   +3 more sources

Malignant mesothelioma

Lancet, The, 2005
exaly